- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Sectors
AbSci absorbs $125m
New and existing investors provided crossover financing for the synthetic biology technology developer, which already counts Merck & Co, AGC Asahi Glass and JSR Life Sciences as investors.
Mar 25, 2021Recursion takes steps toward $100m IPO
Bayer could exit the drug discovery technology developer should it complete an initial public offering on the Nasdaq Global Select Market.
Mar 25, 2021Renovacor reaches reverse merger deal
The Novartis-backed gene therapy developer will merge with Chardan Healthcare Acquisition 2 Corp and take a New York Stock Exchange listing.
Mar 25, 2021Baraja bags series B funding
Newly minted strategic partner Hitachi Construction Machinery was among the investors in a $30.4m round for the lidar system developer.
Mar 25, 2021Asher Bio assesses $55m series A
Asher Bio has launched with $55m in series A financing to commercialise research partially conducted at WashU and Leiden.
Mar 25, 2021Helsinn hails 3B Future Health Fund II
Helsinn is co-anchoring the second 3B Future Health Fund, which will target oncology and rare disease therapeutics startups as it seeks a $118m close.
Mar 25, 2021Roambee raises over $18m
The supply chain software provider, which counts Telkom Indonesia, Deutsche Telekom, Jebsen & Jessen and Telkomsel as investors, has now raised over $42m in total.
Mar 24, 2021GV engages with nPlan
The risk management software developer secured $17.9m in a GV-led round that included LocalGlobe and Entrepreneur First.
Mar 24, 2021UiPath closes Cloud Elements acquisition
API integration platform developer Cloud Elements has been acquired after raising more than $46m from investors including American Express Ventures.
Mar 24, 20211910 Genetics makes $22m date with Microsoft
M12 co-led a $22m series A round for the drug discovery technology developer with Playground Global, and both investors have taken board seats.
Mar 24, 2021AppliedVR accelerates with $29m
Cedars-Sinai contributed to a round boosting the virtual reality therapeutics developer's overall funding to $35m.
Mar 24, 2021Featured Content
GCVI Summit 2026 RewindRewatch the sessions, recap the learningsGCVI Summit 2026 Rewind
Rewatch the sessions, recap the learnings
The World of Corporate VenturingGCV's annual report on the state of the corporate investment sectorThe World of Corporate Venturing
GCV's annual report on the state of the corporate investment sector
GCV’s Rising Stars and Emerging Leaders 2026The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.GCV’s Rising Stars and Emerging Leaders 2026
The talent pipeline in corporate venturing shows both momentum and staying power, as the industry comes of age.
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
